FDA Accepts Submission to Add PH-ILD to YUTREPIA™ Lab

Sets PDUFA goal date of January 24, 2024If approved, YUTREPIA would be indicated for treatment of both PAH and PH-ILD MORRISVILLE, N.C., Sept. 25, 2023 -- Liquidia Corporation announced today...

Related Keywords

Delaware , United States , America , Jason Adair , Us District Court , York Heart Association , Liquidia Corporation The Company , Liquidia Corporation , Liquidia Technologies Inc , United Therapeutics Corporation , Drug Administration , Prescription Drug User Fee Act , Rajeev Saggar , Chief Medical Officer , United Therapeutics , New York Heart Association , Functional Class , Dry Powder Inhalation , Liquidia Technologies , Private Securities Litigation Reform Act , Markets ,